OncoMatch/Clinical Trials/NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Is NCT06119581 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: LY3537982 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed — The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C mutation
Must have disease with evidence of KRAS G12C mutation
Required: PD-L1 (CD274) expression ≥50% (≥50%)
Part A: Greater than or equal to (≥)50 percent (%)
Required: PD-L1 (CD274) expression 0% to 100% (0% to 100%)
Part B: 0% to 100%
Required: PD-L1 (CD274) expression <50% (<50%)
Part C: <50%
Required: EGFR validated targetable oncogenic driver mutation or alteration
Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.
Required: ALK validated targetable oncogenic driver mutation or alteration
Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.
Required: BRAF V600E
BRAF (V600E)
Required: HER2 (ERBB2) validated targetable oncogenic driver mutation or alteration
human epidermal growth factor receptor 2 (HER2)
Required: MET exon 14 mutation
MET (exon 14)
Required: ROS1 validated targetable oncogenic driver mutation or alteration
ROS1
Required: RET validated targetable oncogenic driver mutation or alteration
rearranged during transfection (RET)
Required: NTRK1 validated targetable oncogenic driver mutation or alteration
neurotrophic tyrosine receptor kinase (NTRK)1
Required: NTRK2 validated targetable oncogenic driver mutation or alteration
neurotrophic tyrosine receptor kinase (NTRK)2
Required: NTRK3 validated targetable oncogenic driver mutation or alteration
neurotrophic tyrosine receptor kinase (NTRK)3
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clearview Cancer Institute · Huntsville, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Banner University Medical Center Phoenix · Phoenix, Arizona
- The University of Arizona Cancer Center - North Campus · Tucson, Arizona
- Highlands Oncology Group · Springdale, Arkansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify